Title: Tyloxapol
CAS Registry Number: 25301-02-4
CAS Name: 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane
Additional Names: oxyethylated tertiary octylphenol formaldehyde polymer; p-isooctylpolyoxyethylenephenol formaldehyde polymer; tyloxypal
Trademarks: Alevaire (Sanofi Winthrop); Superinone (Sanofi Winthrop); Triton A-20 (Rohm & Haas); Triton WR-1339 (Rohm & Haas)
Literature References: Nonionic detergent with surface-tension-reducing properties. Prepn: Bock, Rainey, US 2454541 (1948 to Rohm & Haas); J. W. Cornforth et al., Nature 168, 150 (1951). Use to induce exptl hyperlipidemia: A. Kellner et al., J. Exp. Med. 93, 373 (1951); P. E. Schurr et al., Lipids 7, 68 (1972). Use as ophthalmic excipient: D. E. Guttman et al., J. Pharm. Sci. 50, 305 (1961). Phase behavior of mixtures with water: K. Westesen, Int. J. Pharm. 102, 91 (1994); K. Westesen, M. H. J. Koch, ibid. 103, 225 (1994). Tissue distribution and excretion: R. L. DeAngelis et al., Xenobiotica 25, 521 (1995).
Properties: d20 1.0963. Cloud point: 92-97°. Slowly but freely misc with water. Sol in benzene, toluene, chloroform, carbon tetrachloride, carbon disulfide, acetic acid. Alkaline pH. Oxidized by metals.
Density: d20 1.0963
Derivative Type: Combination with colfosceril palmitate and hexadecanol see Exosurf®
Use: Pharmaceutic aid (dispersing agent; excipient). To induce exptl hyperlipidemia in animal models.
Therap-Cat: Mucolytic.
Keywords: Mucolytic.
Tymazoline Tyramine Tyrocidine Tyropanoate Sodium Tyrosinase

Systematic (IUPAC) name
Clinical data
AHFS/Drugs.com International Drug Names
Legal status  ?
CAS number 25301-02-4 YesY
ATC code R05CA01
PubChem CID 71388
DrugBank DB06439
ChemSpider 11052515 N
KEGG D03261 N
Chemical data
Formula (C15H21O(C2H4O)m)n
Mol. mass variable
 N (what is this?)  (verify)

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.

With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]